The effect of renal dysfunction on circulating Sclerostin level in patients with type 2 diabetes

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Kim, Se Hwa ^a   Yoon, Soo Young ^a   Lim, Sung Kil ^b   Rhee, Yumie ^b  

^a Kwandong University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; SCLEROSTIN;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; UPREGULATION;

EID: 84904157937     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/715908     Document Type: Article

References (20)

1. Poole K. E. S., Van Bezooijen R. L., Loveridge N., Hamersma H., Papapoulos S. E., Löwik C. W., Reeve J., Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB Journal 2005 19 13 1842 1844 10.1096/fj.05-4221fje 2-s2.0-27744461726 (Pubitemid 41598769)
2. Baron R., Rawadi G., Minireview: targeting the Wnt/ β -catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007 148 6 2635 2643 10.1210/en.2007-0270 2-s2.0-34250823973 (Pubitemid 46984775)
3. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., Harris S. E., Wu D., Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Journal of Biological Chemistry 2005 280 20 19883 19887 10.1074/jbc.M413274200 2-s2.0-21244480924 (Pubitemid 41379516)
4. Mödder U. I., Hoey K. A., Amin S., McCready L. K., Achenbach S. J., Riggs B. L., Melton L. J. III, Khosla S., Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. Journal of Bone and Mineral Research 2011 26 2 373 379 10.1002/jbmr.217 2-s2.0-77957846460
5. Amrein K., Amrein S., Drexler C., Dimai H. P., Dobnig H., Pfeifer K., Tomaschitz A., Pieber T. R., Fahrleitner-Pammer A., Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. Journal of Clinical Endocrinology and Metabolism 2012 97 1 148 154 10.1210/jc.2011-2152 2-s2.0-84855474270
6. Garcia-Martin A., Rozas-Moreno P., Reyes-Garcia R., Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2012 97 1 234 241 10.1210/jc.2011-2186
7. Rhee Y., Kim S. J., Han K. J., Lim S. K., Kim S. H., Effect of liver dysfunction on circulating sclerostin. Journal of Bone and Mineral Metabolism 2013 10.1007/s00774-013-0524-z
8. Cejka D., Herberth J., Branscum A. J., Fardo D. W., Monier-Faugere M., Diarra D., Haas M., Malluche H. H., Sclerostin and dickkopf-1 in renal osteodystrophy. Clinical Journal of the American Society of Nephrology 2011 6 4 877 882 10.2215/CJN.06550810 2-s2.0-79955552110
9. Pelletier S., Dubourg L., Carlier M., Hadj-Aissa A., Fouque D., The relation between renal function and serum sclerostin in adult patients with CKD. Clinical Journal of the American Society of Nephrology 2013 8 5 819 823 10.2215/CJN.07670712 2-s2.0-84877641819
10. Mirza F. S., Padhi I. D., Raisz L. G., Lorenzo J. A., Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2010 95 4 1991 1997 10.1210/jc.2009-2283 2-s2.0-77951644377
11. Sabbagh Y., Graciolli F. G., O'Brien S., Tang W., Dos Reis L. M., Ryan S., Phillips L., Boulanger J., Song W., Bracken C., Liu S., Ledbetter S., Dechow P., Canziani M. E. F., Carvalho A. B., Jorgetti V., Moyses R. M. A., Schiavi S. C., Repression of osteocyte Wnt/ β -catenin signaling is an early event in the progression of renal osteodystrophy. Journal of Bone and Mineral Research 2012 27 8 1757 1772 10.1002/jbmr.1630 2-s2.0-84864152751
12. Cejka D., Marculescu R., Kozakowski N., Renal elimination of sclerostin increases with declining kidney function. Journal of Clinical Endocrinology and Metabolism 2014 99 1 248 255 10.1210/jc.2013-2786
13. Keller H., Kneissel M., SOST is a target gene for PTH in bone. Bone 2005 37 2 148 158 10.1016/j.bone.2005.03.018 2-s2.0-21844467220 (Pubitemid 40962421)
14. Bellido T., Ali A. A., Gubrij I., Plotkin L. I., Fu Q., O'Brien C. A., Manolagas S. C., Jilka R. L., Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005 146 11 4577 4583 10.1210/en.2005-0239 2-s2.0-26844521277 (Pubitemid 41446595)
15. van Lierop A. H., Witteveen J. E., Hamdy N. A. T., Papapoulos S. E., Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. European Journal of Endocrinology 2010 163 5 833 837 10.1530/EJE-10-0699 2-s2.0-77957838571
16. Thambiah S., Roplekar R., Manghat P., Fogelman I., Fraser W. D., Goldsmith D., Hampson G., Circulating sclerostin and dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): Relationship with bone density and arterial stiffness. Calcified Tissue International 2012 90 6 473 480 10.1007/s00223-012-9595-4 2-s2.0-84864280719
17. Gennari L., Merlotti D., Valenti R., Ceccarelli E., Ruvio M., Pietrini M. G., Capodarca C., Franci M. B., Campagna M. S., Calabrò A., Cataldo D., Stolakis K., Dotta F., Nuti R., Circulating Sclerostin levels and bone turnover in type 1 and type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2012 97 5 1737 1744 10.1210/jc.2011-2958 2-s2.0-84860714853
18. Ferreira J. C., Ferrari G. O., Neves K. R., Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease-role of sclerostin? PLoS ONE 2013 8 11 e79721 10.1371/journal.pone.0079721
19. Kirmani S., Amin S., McCready L. K., Atkinson E. J., Melton L. J. III, Müller R., Khosla S., Sclerostin levels during growth in children. Osteoporosis International 2012 23 3 1123 1130 10.1007/s00198-011-1669-z 2-s2.0-84857442198
20. Ardawi M. M., Al-Kadi H. A., Rouzi A. A., Qari M. H., Determinants of serum sclerostin in healthy pre- and postmenopausal women. Journal of Bone and Mineral Research 2011 26 12 2812 2822 10.1002/jbmr.479 2-s2.0-81855184668